Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 9

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 9
---
5

| offering. We currently intend to use the net proceeds from this offering for working capital, satisfaction of the Company’s $3.4 million bridge note obligation to the Matthew Nachtrab 
 Revocable Trust (net of $1.75 million invested by such lender into this offering), and general corporate purposes. See “Use of Proceeds” on page S-8 of this prospectus supplement.     |

| Risk factors | See “ Risk Factors” on page S-4 and the other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of certain 
 factors you should carefully consider before deciding to invest in shares of our Common Stock or the Warrants.                                                                            |

| (1) | The number of shares of Common Stock to be outstanding after the offering is based on 51,258,085 shares of 
 Common Stock outstanding at November 20, 2025 and excludes the following as of November 20, 2025:          |

| • |     | 8,681,079 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted exercise 
 price of $4.61 per share;                                                                                       |

| • |     | 7,521,208 shares of Common Stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity 
 Incentive Plan;                                                                                              |

| • |     | 13,450,711 shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted exercise price 
 of $4.55 per share;                                                                                               |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the                                                 
 Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject             
 to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

S-6

RISK FACTORS

You should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks we are not presently aware of or that we currently believe are immaterial may also impair our